Abstract: GDM is a problem that affects a significant number of women during pregnancy. Gestational diabetes mellitus (GDM) occurs when a woman’s pancreatic function is not sufficient to overcome the diabetogenic environment of pregnancy. GDM is defined as glucose intolerance that was not present or recognized prior to pregnancy. The aim of present study was to determine the prevalence of gestational diabetes mellitus in polycystic ovary syndrome. The study was a retrospective observational study and conducted at Disha fertility & Surgical Center Indore and other hospitals like CHL Apollo. Assessment of random blood sugar, fasting blood sugar, Post Prandial, oral GTT, glucose load test, HbA1c & risk factor were done during 24 -28th week of gestation in GDM and Non GDM group. Significant increases were observed in all the type of glucose testing in GDM group as compared to control and Non GDM group. Gestational diabetes mellitus has a high prevalence in patients with polycystic ovary syndrome. A consensus between early detection and classification criteria to standardize the diagnosis should be sought.

Keyword: Glucose intolerance, Polycystic ovary syndrome, Pregnancy, HbA1c

1. Introduction

Gestational diabetes mellitus (GDM), defined as carbohydrate intolerance at onset of pregnancy (or first recognition), affects 4–7 % of pregnancies overall (1–6). Common risk factors include on white race/ethnicity, older age, obesity, and prior GDM (3–7). Other conditions predisposing to glucose intolerance might also increase the risk of GDM.

Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine and metabolic disorder with a prevalence between 5 - 15% in women of reproductive age [8,9]. According to the Rotterdam consensus [10], PCOS is defined as the presence of two of the following criteria: hyperandrogenism, ovulatory dysfunction and polycystic ovaries on ultrasound (12) or more follicles, 2-9 mm in diameter, and/or increased ovarian volume >10 ml. Disorders that mimic the clinical features of PCOS are excluded [8-13].

PCOS. These alterations can lead to glucose metabolism disorders and increased risk of developing gestational diabetes mellitus (GDM). Furthermore, pregnancy itself induces insulin resistance [8,9,11,12]

Polycystic ovary syndrome (PCOS) is a reproductive condition characterized by chronic an ovulation, insulin resistance, and androgen excess (14–16). Affected women have an increased risk of glucose intolerance and type 2 diabetes (17–20). Some, but not all, studies suggest the risk of GDM is higher among PCOS versus non-PCOS women (21–24), and several studies note an increased prevalence of polycystic ovarian morphology and symptoms in women with prior GDM (25–27). The aim of present study was to get aware about the increased risk for developing GDM in their pregnancies.

2. Material and method

This study was conducted during January 2012 to May 2012 on GDM outdoor and indoor patients of Disha fertility & Surgical Center Indore. Consent was taken from each person involved in the study.

Experimental Design

The present study was conducted on 60 subjects. Studied subjects were divided in the following three groups-

A. Control Group: In this group, 20 normal healthy subjects were included, which were free from any illness by clinical examination not pregnant.

B. Non GDM: In this group, 20 Non GDM pregnant women, with no active medical complication were included.

C. GDM group: In this group, 20 GDM patients were included having history of PCOS.

The patients suffering from other diseases such as Diabetes before pregnancy, inflammatory disease, cardiac disease, hepatic impairment and respiratory diseases or other systemic disease as well as smokers and alcoholics were excluded from the study.

Following glucose test was carried out:

- Random Blood Sugar
- Fasting Blood Glucose
- Post-Prandial Blood Glucose
- Oral Glucose Tolerance Test (0, 1 & 2 Hrs)
- Glucose Load Test
- HbA1C

Determination of serum glucose was done by GOD/POD method (Glucose oxidase/ Peroxidase) (28) Determination of HbA1C in serum or Blood was done by NycoCard HbA1C (Boronate affinity assay kit) (29). The result were presented as mean ± standard deviation, and categorical data were expressed as count and proportions. Student T-Test was used to compare parametric continuous variables between GDM
and non-GDM groups. All the statistical processes were carried out using SPSS version 15 and P-value <0.05 was considered as significant.

3. Result

All studied groups belonged to the age group of 25-35 and the mean age was 30.5 ± 2.45, 28.35 ± 3.58 and 29.8 ± 2.98 year in GDM, control and Non GDM respectively. Random blood sugar in terms of mean ± SD in Non GDM was (97 ± 10.7), this increased was highly significant (t, df, p) (40.49, 19, p<0.0000) when compared with age matched normal healthy control (81.7± 8.06). Random blood sugar in terms of mean ± SD was (170.2 ± 91.6) in GDM, this increased was highly significant (t, df, p) (8.30, 19, p<0.0000) when compared with age matched normal healthy control. FBS in terms of mean ± SD was (81.35 ± 5.26) in Non GDM, this increased was highly significant (t, df, p) (69.10, 19, p<0.0000) when compared with age matched normal healthy control. FBS in terms of mean ± SD was (96.8 ± 24.8) in GDM, this raised was highly significant (t, df, p) (17.39, 19, p<0.0000) when compared with age matched normal healthy control (76.65 ± 9.15). Post Prandial glucose levels in terms of mean ± SD was (113.5 ± 10.07) in Non GDM. This increased was highly significant (t, df, p) (50.42, 19, p<0.0001) when compared with a normal healthy control group. Post Prandial glucose levels in terms of mean ± SD was (160.4 ± 21.11) in GDM. This increased was highly significant (t, df, p) (33.96, 19, p<0.0000) when compared with age matched normal healthy control (84.05 ± 11.02). HbA1C levels in terms of mean ± SD was (5.79 ± 1.2) in GDM, GLT levels in terms of mean ± SD was (109.9 ± 21.9) in Non GDM. This increased was highly significant (t, df, p) (22.40, 19, p<0.0001) when compared with a normal healthy control group. GLT levels in terms of mean ± SD was (188.4 ± 18.1) in GDM.

4. Discussion

The time of screening was generally between the 24th and 28th week of gestation. In RBS and PP glucose level is significant in GDM patient having history of PCOS compared with control. This study shows that the insulin resistance increase as in pregnancy than the non pregnant women. The priming of the fetal beta cells may account for the persistence of fetal hyperinsulinemia throughout pregnancy and the risk of accelerated fetal growth. The present study supports that GLT in Non GDM and GDM was significantly high as compare to Control.

GLT level was significantly increased in Non GDM as compare to control, while in GDM it was also significantly increased as compare to control and Non GDM. WHO criteria based on glucose concentration 2 h after 75 gm glucose load was able to correctly identify subjects with GDM (Pettitt DJ, et al; 1994) The present study support that the GCT or GLT (75 gm- 2 hour GLT) can be used for diagnosis of GDM having history of PCOS. The present findings support the hypothesized association between GDM study that suggest the 18-month follow-up, a significant improvement in the OGTT parameters and in the IGT and IFG-IGR incidence were observed in the control group. Statistical significance compared with the controls for all end points except DM, which was likely due to the small sample studied. The present study finding was against the previous study finding that show no significant (P = 0.776) difference between the GDM cases and controls was detected in the incidence of patients with IGT (6 [14.3%] vs. 14 [16.7%], respectively) and IFG (5 [11.9%] vs. 15 [17.9%], respectively). HbA1C were higher in GDM group than those in control, Non GDM group, and these findings support the hypothesized association between GDM and subsequent PCOS and metabolic syndrome women in whom glucose intolerance was diagnosed in early pregnancy as pre GDM, GDM, or normal glucose tolerant.

5. Conclusion

This study concluded that the diagnosis of GDM is done in 24 – 28 week of pregnancy. Women with PCOS who want to have children must be informed about the increased risk for developing GDM in their pregnancies. Metabolic findings in PCOS include increased. Insulin resistance, dyslipidemia, and elevated androgen levels - often accompanied by infertility and infertility treatments in order to achieve pregnancy. Confounding factors, such as obesity and the diverse ovulation induction treatments in infertile women with PCOS, can be considered potentially risk-increasing variables. Those coexisting factors, together with additional predisposing factors, such as a positive family history for diabetes mellitus, have been suggested to correlate with a generally increased risk for developing GDM and impaired glucose tolerance (Toulis et al., 2009).

Comparable pathophysiological mechanisms of insulin resistance and impaired glucose tolerance can be found in GDM and in women with PCOS who demonstrate an increased tissue resistance to insulin. However, the exact pathophysiological link between PCOS and GDM has not yet been fully elucidated.
Table: Showing the blood glucose level (mg/dl) in the studied blood glucose test and value of HbA1c in control, Non GDM and GDM subject.

<table>
<thead>
<tr>
<th>Name of test</th>
<th>Blood Glucose Level (mg/dl)</th>
<th>Control</th>
<th>Non GDM</th>
<th>GDM</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBS</td>
<td>81.7 ± 8.066</td>
<td>97±10.711</td>
<td>170.25±91.65</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>FBS</td>
<td>76.65 ± 9.155</td>
<td>81.35±5.264</td>
<td>96.8±24.88</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>PP</td>
<td>96.65 ± 13.07</td>
<td>113.5±10.07</td>
<td>160.4±21.19</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>One hour GTT</td>
<td>101.85±10.599</td>
<td>139.±19.783</td>
<td>198±29.531</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>Two hour GTT</td>
<td>84.05 ± 11.023</td>
<td>98.51±8.086</td>
<td>179.1±37.984</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>HbA1C (%)</td>
<td>4.31 ± 0.512</td>
<td>4.75±0.5041</td>
<td>5.79±1.299</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
<tr>
<td>GLT</td>
<td>100.1 ± 7.210</td>
<td>107.9±21.93</td>
<td>188.4±18.126</td>
<td>a/b/c =.000</td>
<td></td>
</tr>
</tbody>
</table>

- P value control versus Non GDM, b- P value the control versus GDM, c- P value NonGDM versus GDM

Graph: Showing HbA1c % level comparison in GDM, Non GDM and Control

References


Detected by the National Diabetes Data Group or the Carpenter and Coustan Plasma Glucose Thresholds American Diabetes Association: Gestational Diabetes Care 23 (Suppl. 1):S77–S79, 2000


